US Bancorp’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.2M Buy
275,250
+23,563
+9% +$1.01M 0.01% 388
2026
Q1
$9.25M Buy
251,687
+27,274
+12% +$1.29M 0.01% 431
2025
Q4
$11.4M Sell
224,413
-44,950
-17% -$2.3M 0.01% 406
2025
Q3
$14.9M Sell
269,363
-30,103
-10% -$1.76M 0.02% 368
2025
Q2
$20.7M Sell
299,466
-39,004
-12% -$2.65M 0.03% 317
2025
Q1
$23.5M Buy
338,470
+3,493
+1% +$288K 0.03% 292
2024
Q4
$28.8M Sell
334,977
-31,858
-9% -$3.45M 0.04% 262
2024
Q3
$43.7M Buy
366,835
+231
+0.1% +$30.8K 0.06% 211
2024
Q2
$52.3M Sell
366,604
-27,578
-7% -$3.65M 0.07% 184
2024
Q1
$50.6M Sell
394,182
-11,488
-3% -$1.37M 0.07% 187
2023
Q4
$42M Buy
405,670
+11,729
+3% +$1.16M 0.06% 198
2023
Q3
$35.8M Sell
393,941
-1,729
-0.4% -$152K 0.06% 208
2023
Q2
$32M Buy
395,670
+27,862
+8% +$2.28M 0.05% 226
2023
Q1
$29.3M Buy
367,808
+41,530
+13% +$2.94M 0.05% 238
2022
Q4
$22.1M Sell
326,278
-12,742
-4% -$747K 0.04% 272
2022
Q3
$16.9M Buy
339,020
+1,624
+0.5% +$87K 0.03% 279
2022
Q2
$18.8M Buy
337,396
+3,978
+1% +$221K 0.04% 281
2022
Q1
$18.5M Sell
333,418
-24,102
-7% -$1.24M 0.03% 313
2021
Q4
$20M Buy
357,520
+57,320
+19% +$3.11M 0.03% 300
2021
Q3
$14.4M Buy
300,200
+38,174
+15% +$1.85M 0.03% 331
2021
Q2
$11M Sell
262,026
-2,332
-0.9% -$90.4K 0.02% 383
2021
Q1
$8.91M Sell
264,358
-38,872
-13% -$1.38M 0.02% 421
2020
Q4
$10.6M Sell
303,230
-8,650
-3% -$299K 0.02% 367
2020
Q3
$10.8M Buy
311,880
+32,776
+12% +$1.09M 0.03% 346
2020
Q2
$9.14M Sell
279,104
-1,858
-0.7% -$59.3K 0.02% 370
2020
Q1
$8.46M Sell
280,962
-97,864
-26% -$2.91M 0.03% 348
2019
Q4
$11M Sell
378,826
-23,850
-6% -$660K 0.03% 350
2019
Q3
$10.4M Sell
402,676
-54,648
-12% -$1.38M 0.03% 353
2019
Q2
$11.7M Sell
457,324
-152,242
-25% -$3.76M 0.03% 342
2019
Q1
$15.9M Sell
609,566
-484
-0.1% -$11.9K 0.05% 285
2018
Q4
$14.1M Buy
610,050
+83,572
+16% +$1.86M 0.05% 282
2018
Q3
$12.4M Sell
526,478
-9,168
-2% -$224K 0.04% 325
2018
Q2
$12.4M Buy
535,646
+76,330
+17% +$1.81M 0.04% 312
2018
Q1
$11.3M Sell
459,316
-6,830
-1% -$179K 0.03% 332
2017
Q4
$12.5M Buy
466,146
+12,240
+3% +$311K 0.04% 312
2017
Q3
$10.9M Buy
453,906
+23,426
+5% +$529K 0.04% 328
2017
Q2
$9.23M Sell
430,480
-7,918
-2% -$160K 0.03% 353
2017
Q1
$7.51M Buy
438,398
+43,186
+11% +$752K 0.03% 394
2016
Q4
$7.09M Sell
395,212
-65,082
-14% -$1.18M 0.03% 398
2016
Q3
$9.57M Sell
460,294
-6,298
-1% -$156K 0.04% 335
2016
Q2
$12.5M Sell
466,592
-49,936
-10% -$1.37M 0.05% 296
2016
Q1
$14M Sell
516,528
-214,490
-29% -$5.75M 0.06% 266
2015
Q4
$21.2M Sell
731,018
-98,556
-12% -$2.73M 0.09% 197
2015
Q3
$22.5M Sell
829,574
-8,612
-1% -$244K 0.09% 187
2015
Q2
$22.9M Buy
838,186
+49,154
+6% +$1.38M 0.09% 201
2015
Q1
$21.1M Buy
789,032
+15,296
+2% +$352K 0.08% 215
2014
Q4
$16.4M Buy
773,736
+12,454
+2% +$278K 0.06% 248
2014
Q3
$18.1M Buy
761,282
+40,090
+6% +$923K 0.07% 215
2014
Q2
$16.7M Buy
721,192
+8,522
+1% +$188K 0.07% 230
2014
Q1
$16.3M Buy
712,670
+34,470
+5% +$734K 0.07% 227
2013
Q4
$12.5M Buy
678,200
+52,240
+8% +$910K 0.05% 270
2013
Q3
$10.6M Buy
625,960
+21,150
+3% +$356K 0.05% 278
2013
Q2
$9.37M Buy
+604,810
New +$10.1M 0.04% 303

Other funds holding NVO

US Bancorp's NVO Position: Q2 2026 in Review

US Bancorp increased its Novo Nordisk (NVO) stake by 9.4% in Q2 2026, buying an estimated $1.01M and bringing the position to 275,250 shares worth $13.2M. The position accounts for 0.01% of the portfolio, ranked #388.

US Bancorp first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $52.3M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • US Bancorp held 275,250 shares of Novo Nordisk worth $13.2M as of Q2 2026.
  • US Bancorp bought 23,563 Novo Nordisk shares in Q2 2026, an estimated $1.01M.
  • Novo Nordisk made up 0.01% of US Bancorp's portfolio in Q2 2026, its #388 holding.
  • US Bancorp first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • US Bancorp's Novo Nordisk position peaked at $52.3M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.